Adding-on nivolumab to chemotherapy-stabilized patients is associated with improved survival in advanced pancreatic ductal adenocarcinoma

Background Immune checkpoint inhibitors (ICIs) are rarely used to treat advanced pancreatic ductal adenocarcinoma (PDAC) due to marginal efficacy. Patients and methods This study included 92 consecutive patients diagnosed with advanced or recurrent PDAC who received nivolumab-based treatment. Univar...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy : CII Immunotherapy : CII, 2024-09, Vol.73 (11), p.227, Article 227
Main Authors: Yang, Shih-Hung, Kuo, Sung-Hsin, Lee, Jen-Chieh, Chen, Bang-Bin, Shan, Yan-Shen, Tien, Yu-Wen, Chiu, Sz-Chi, Cheng, Ann-Lii, Yeh, Kun-Huei
Format: Article
Language:English
Subjects:
Adenocarcinoma
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer Research
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - mortality
Carcinoma, Pancreatic Ductal - pathology
CD8 antigen
Chemotherapy
Disease control
Female
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immunology
Lymphocytes T
Male
Medical prognosis
Medicine
Medicine & Public Health
Middle Aged
Nivolumab - administration & dosage
Nivolumab - therapeutic use
Oncology
Pancreas
Pancreatic cancer
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - mortality
Prognosis
Retrospective Studies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Immune checkpoint inhibitors (ICIs) are rarely used to treat advanced pancreatic ductal adenocarcinoma (PDAC) due to marginal efficacy. Patients and methods This study included 92 consecutive patients diagnosed with advanced or recurrent PDAC who received nivolumab-based treatment. Univariate and multivariate analyses were used to identify prognostic factors. A control group of 301 patients with PDAC who achieved disease control with palliative chemotherapy but without ICIs was selected for comparison using propensity score matching (PSM). Results The median overall survival (OS) since nivolumab treatment was 15.8 (95% confidence interval [CI], 12.5–19.0), 2.4 (95% CI 1.2–3.6), and 1.1 (95% CI 1.0–1.2) months in patients who received add-on nivolumab after achieving disease control with chemotherapy, in those who received concomitant nivolumab and chemotherapy without prerequisite confirmation of disease control, and in those who received nivolumab without concomitant chemotherapy, respectively ( P  
ISSN:1432-0851
0340-7004
1432-0851
DOI:10.1007/s00262-024-03821-3